Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Company-sponsored webinar to be announcedCAMBRIDGE, Mass., May 11, 2023 -- Editas Medicine, Inc. , a clinical stage genome editing company, today announced that a scientific abstract detailing... | May 11, 2023

Related Keywords

United States ,Frankfurt ,Brandenburg ,Germany ,Cambridge ,Cambridgeshire ,United Kingdom ,Baisong Mei ,Rabi Hanna ,Harvard University Cas ,Department Of Pediatric Hematology Oncology ,European Hematology Association Congress ,Broad Institute Cas ,European Hematology Association ,Nasdaq ,Editas Medicine Inc ,Broad Institute ,Hybrid Congress ,Senior Vice President ,Chief Medical Officer ,Presentation Details ,Promising Preliminary Safety ,Efficacy Results ,Efficient Ascas ,Pediatric Hematology Oncology ,Marrow Transplantation ,Cleveland Clinic Children ,Editas Medicine ,Harvard University ,Nc Stock Exchange ,News ,Information ,Press Release ,Ebinar ,O ,The ,Bay ,023 ,Yeditas ,Linical ,Stage ,Enome ,Editing ,Oday ,Nnounced ,Hat ,Cientific ,Bstract Edit Us28106w1036 ,